No formal reproductive and developmental toxicology studies were conducted. Justification: The biodistribution study in NHPs did not show any detectable vector DNA in the gonads (testes or ovaries) at any time point up to 3 months post-administration. Therefore, the risk of germline transmission is considered negligible. This approach is consistent with regulatory guidance for AAV-based gene therapies.